Fig. 4

Nicotinamide also promotes pancreatic differentiation through ROCK inhibition. a RT-qPCR analysis of pancreatic progenitors on day 13 treated with nicotinamide and Y27632 to measure mRNA levels of NKX6.1, PDX1, PTF1A and SOX9 (n > 3), *p < 0.05; b Immunostaining for PDX and NKX6.1 expression under Mock, nicotinamide and Y27632 conditions, Scale bar 100 μm (n = 3); c Flow cytometry analysis of pancreatic progenitors on day 13 for PDX1⁺ and NKX6.1⁺ percentage under Mock, nicotinamide and Y27632 conditions (n = 3); d, d` Western blot analysis of p-MLC2 (Ser19) in stage 4 (from day 10 to day 13) (n = 3), *p < 0.05; e, e` Western blot analysis of p-MLC2 (Ser19) in day 13 pancreatic progenitors under Mock, nicotinamide, Y27632 and D4476 conditions (n = 3), *p < 0.05